ATE451926T1 - Zusammensetzung enthaltend einen hmg-coa- reduktasehemmer und eine nikotinsäureverbindung zur behandlung von hyperlipidämie - Google Patents

Zusammensetzung enthaltend einen hmg-coa- reduktasehemmer und eine nikotinsäureverbindung zur behandlung von hyperlipidämie

Info

Publication number
ATE451926T1
ATE451926T1 AT07003276T AT07003276T ATE451926T1 AT E451926 T1 ATE451926 T1 AT E451926T1 AT 07003276 T AT07003276 T AT 07003276T AT 07003276 T AT07003276 T AT 07003276T AT E451926 T1 ATE451926 T1 AT E451926T1
Authority
AT
Austria
Prior art keywords
nicotinic acid
nicotinamide
methyl
hmg
coa reductase
Prior art date
Application number
AT07003276T
Other languages
English (en)
Inventor
David J Bova
Josephine Dunne
Original Assignee
Abbott Respiratory Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Respiratory Llc filed Critical Abbott Respiratory Llc
Application granted granted Critical
Publication of ATE451926T1 publication Critical patent/ATE451926T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT07003276T 1997-07-31 1998-07-31 Zusammensetzung enthaltend einen hmg-coa- reduktasehemmer und eine nikotinsäureverbindung zur behandlung von hyperlipidämie ATE451926T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US90375297A 1997-07-31 1997-07-31

Publications (1)

Publication Number Publication Date
ATE451926T1 true ATE451926T1 (de) 2010-01-15

Family

ID=25418027

Family Applications (2)

Application Number Title Priority Date Filing Date
AT07003276T ATE451926T1 (de) 1997-07-31 1998-07-31 Zusammensetzung enthaltend einen hmg-coa- reduktasehemmer und eine nikotinsäureverbindung zur behandlung von hyperlipidämie
AT98938228T ATE359785T1 (de) 1997-07-31 1998-07-31 Manteltablette enthaltend nikotinsäure oder einen stoff, der zu nikotinsäure metabolisiert wird, in verzögert freigesetzter form, und einen hmg-coa reduktasehemmer im mantel zur sofortigen freisetzung

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT98938228T ATE359785T1 (de) 1997-07-31 1998-07-31 Manteltablette enthaltend nikotinsäure oder einen stoff, der zu nikotinsäure metabolisiert wird, in verzögert freigesetzter form, und einen hmg-coa reduktasehemmer im mantel zur sofortigen freisetzung

Country Status (17)

Country Link
US (3) US20040053975A1 (de)
EP (2) EP1017390B1 (de)
JP (2) JP4870869B2 (de)
AT (2) ATE451926T1 (de)
AU (1) AU752673B2 (de)
BR (1) BR9815548A (de)
CA (1) CA2298549C (de)
CY (1) CY1107057T1 (de)
DE (2) DE69841395D1 (de)
DK (1) DK1017390T3 (de)
ES (2) ES2283067T3 (de)
HK (1) HK1106153A1 (de)
IL (2) IL134271A0 (de)
NO (1) NO20000439L (de)
NZ (1) NZ520176A (de)
PT (1) PT1017390E (de)
WO (1) WO1999006035A2 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE970731A1 (en) † 1997-10-07 2000-10-04 Fuisz Internat Ltd Product and method for the treatment of hyperlipidemia
DE19858789A1 (de) * 1998-12-18 2000-06-21 Bayer Ag Kombination von Cerivastatin und Fibraten
US6569461B1 (en) 1999-03-08 2003-05-27 Merck & Co., Inc. Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors
MXPA02000492A (es) * 1999-07-14 2002-07-02 Geltex Pharma Inc Polimeros enlazantes de grasas, opcionalmente combinados con inhibidores de lipasas.
JP2001131151A (ja) * 1999-11-02 2001-05-15 Shionogi & Co Ltd オレフィン誘導体の新規用途
IL139450A0 (en) * 1999-11-10 2001-11-25 Pfizer Prod Inc Methods of administering apo b-secretion/mtp inhibitors
WO2001093859A1 (en) † 2000-06-09 2001-12-13 Lek Pharmaceuticals D.D. Stable pharmaceutical product and formulation
WO2002034261A1 (fr) * 2000-10-23 2002-05-02 Sankyo Company, Limited Compositions hypocholesterolemiantes
US6916849B2 (en) 2000-10-23 2005-07-12 Sankyo Company, Limited Compositions for improving lipid content in the blood
CA2428204A1 (en) 2000-11-07 2002-05-16 Sankyo Company, Limited Lipid peroxide-lowering compositions
TWI284529B (en) * 2000-12-18 2007-08-01 Sankyo Co A composition for lowering triglyceride
ITMI20012366A1 (it) * 2001-11-09 2003-05-09 Farmatron Ltd Sistemi terapeutici stabilizzati a rilascio immediato e/o modificato per la somministrazione orale di principi attivi e/o eccipienti e/o ali
US7176310B1 (en) 2002-04-09 2007-02-13 Ucb Sa Pyrimidinecarboxamide derivatives and their use as anti-inflammatory agents
CN100415235C (zh) * 2002-08-02 2008-09-03 三共株式会社 含有HMG-CoA还原酶抑制剂的药物组合物
JP4607436B2 (ja) * 2002-08-02 2011-01-05 第一三共株式会社 ＨＭＧ−ＣｏＡリダクターゼ阻害剤を含有する医薬組成物
TW200409635A (en) * 2002-08-02 2004-06-16 Sankyo Co A pharmaceutical composition containing a HMG-CoA reductase
SI21402A (sl) * 2003-02-12 2004-08-31 LEK farmacevtska dru�ba d.d. Obloženi delci in farmacevtske oblike
AR041089A1 (es) * 2003-05-15 2005-05-04 Merck & Co Inc Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
RU2006102981A (ru) * 2003-08-04 2007-09-20 Пфайзер Продактс Инк. (Us) Лекарственные формы, обеспечивающие контролируемое высвобождение ингибиторов белка-переносчика эфиров холестерина и немедленное высвобождение ингибиторов hmg-соа-редуктазы
WO2005041878A2 (en) * 2003-10-29 2005-05-12 Tawakol Raif M D Compositions and methods for increasing hdl and hdl-2b levels
US20060229265A1 (en) * 2005-03-30 2006-10-12 Sirtris Pharmaceuticals, Inc. Nicotinamide riboside and analogues thereof
US20070014833A1 (en) * 2005-03-30 2007-01-18 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators
US20060292099A1 (en) * 2005-05-25 2006-12-28 Michael Milburn Treatment of eye disorders with sirtuin modulators
US20070149466A1 (en) * 2005-07-07 2007-06-28 Michael Milburn Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
PT1919466E (pt) * 2005-07-11 2012-05-21 Cortria Corp Formulações para tratamento de anormalidades de lipoproteína compreendendo uma estatina e um derivado de metilnicotinamida
KR20070063350A (ko) * 2005-12-14 2007-06-19 주식회사종근당 서방형 방출층과 속방형 방출층을 포함한 고지혈증 및동맥경화를 치료를 위한 약제학적 조성물
CA2569776A1 (en) * 2006-02-17 2007-08-17 Kos Life Sciences, Inc. Low flush niacin formulation
EP2081550B2 (de) * 2006-03-09 2021-05-26 Reliant Pharmaceuticals, Inc. Beschichtung von kapseln mit pharmazeutischen wirkstoffen
US8784886B2 (en) 2006-03-09 2014-07-22 GlaxoSmithKline, LLC Coating capsules with active pharmaceutical ingredients
WO2008023958A1 (en) * 2006-08-24 2008-02-28 Hanall Pharmaceutical Co., Ltd. Combined pharmaceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors
WO2008023869A1 (en) * 2006-08-24 2008-02-28 Hanall Pharmaceutical Co., Ltd. Combined pharmeceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors
DE102007003524A1 (de) * 2007-01-19 2008-09-04 MEDICE Arzneimittel Pütter GmbH & Co. KG Arzneimittel zur Behandlung und/oder Prävention von Arteriosklerose
KR100885029B1 (ko) 2007-02-07 2009-02-23 지엘팜텍 주식회사 경구투여용 서방성 삼중정제
WO2009016577A2 (en) * 2007-07-27 2009-02-05 Ranbaxy Laboratories Limited A pharmaceutical composition comprising atorvastatin and niacin
WO2009104939A2 (ko) * 2008-02-22 2009-08-27 한올제약주식회사 약제학적 제제
KR100949273B1 (ko) * 2008-02-22 2010-03-25 한올제약주식회사 복합제제
KR20090091075A (ko) * 2008-02-22 2009-08-26 한올제약주식회사 심혈관계 질환 치료용 약제학적 제제
MX2010012514A (es) * 2008-05-20 2011-05-30 Cerenis Therapeutics S A Niacina y un medicamento nsaid para tratamiento combinado.
BRPI0913425A2 (pt) * 2008-06-02 2015-11-24 Reddys Lab Ltd Dr formulações de niacina com liberação modificada
RU2010153904A (ru) * 2008-06-02 2012-07-20 Др. Редди'С Лабораторис Лтд. (In) Ниацин-содержащие композиции с модифицированным высвобождением
US20100178341A1 (en) * 2008-06-11 2010-07-15 Ranbaxy Laboratories Limited BILAYERED TABLET COMPRISING NIACIN AND HMG-CoA REDUCTASE INHIBITOR
EP2310004A1 (de) 2008-07-11 2011-04-20 Kareus Therapeutics SA Niacinzusammensetzungen für verminderte produktion von amyloid-beta-peptid 42 (abeta 42) und zur behandlung von morbus alzheimer
WO2010127346A1 (en) * 2009-05-01 2010-11-04 Eurand, Inc. Orally disintegrating tablet compositions comprising combinations of non-opioid and opioid analgesics
CA2706270C (en) * 2010-06-03 2020-01-07 Accucaps Industries Limited Pharmaceutical formulations of statins and omega-3 fatty acids for encapsulation
KR20200003219A (ko) 2011-05-20 2020-01-08 아스트라제네카 유케이 리미티드 로수바스타틴 칼슘의 약학 조성물
BR112017009876A2 (pt) 2014-11-14 2017-12-19 Gemphire Therapeutics Inc processos e intermediários para a preparação de éteres de dialcano terminados em ácido alfa,ômega-dicarboxílico
MX2018005540A (es) * 2015-11-06 2018-11-09 Gemphire Therapeutics Inc Tratamiento de dislipemia mixta.

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3524001A (en) * 1965-03-04 1970-08-11 Upjohn Co Compositions and method for reducing free fatty acid and cholesterol in the blood of mammals with 3,5 - disubstituted isoxazoles
JPS63310827A (ja) * 1987-06-15 1988-12-19 Sanwa Kagaku Kenkyusho Co Ltd ニコチン酸誘導体を主剤とする徐放性製剤
US5260305A (en) * 1988-12-12 1993-11-09 E. R. Squibb & Sons, Inc. Combination of pravastatin and nicotinic acid or related acid and method for lowering serum cholesterol using such combination
US4933165A (en) * 1989-01-18 1990-06-12 Merck & Co., Inc. Coenzyme Q10 with HMG-CoA reductase inhibitors
US5268181A (en) * 1989-04-13 1993-12-07 Upsher-Smith Laboratories, Inc. Method of using niacin to control nocturnal cholesterol synthesis
CA2016467A1 (en) * 1989-06-05 1990-12-05 Martin Eisman Method for treating peripheral atherosclerotic disease employing an hmg coa reductase inhibitor and/or a squalene synthetase inhibitor
CA2018470A1 (en) * 1989-07-17 1991-01-17 Scott Adams Biller Phosphorus-containing squalene synthetase inhibitors and method
US5135935A (en) * 1991-05-17 1992-08-04 Merck & Co., Inc. Squalene synthetase inhibitors
US5840339A (en) * 1991-07-30 1998-11-24 Kunin; Robert Blood cholesterol reducing pharmaceutical composition
EP0543417A1 (de) * 1991-11-22 1993-05-26 Lipogenics, Incorporated Tocotrienole und Focotrienol-ähnliche Verbindungen und Verfahren zu ihrer Verwendung
US5292534A (en) * 1992-03-25 1994-03-08 Valentine Enterprises, Inc. Sustained release composition and method utilizing xanthan gum and an active ingredient
US5609884A (en) * 1992-08-31 1997-03-11 G. D. Searle & Co. Controlled release naproxen sodium plus naproxen combination tablet
US6129930A (en) * 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US6080428A (en) * 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US6369103B1 (en) * 1994-01-18 2002-04-09 Bristol-Myers Squibb Company Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor
US5582838A (en) * 1994-12-22 1996-12-10 Merck & Co., Inc. Controlled release drug suspension delivery device
US5773453A (en) * 1995-04-19 1998-06-30 Vanderbilt University Methods for administration of antilipemic drugs
AU5787996A (en) * 1995-04-19 1996-11-07 Lipoprotein Technologies, Inc. Compositions, kits, and methods for administration of antilipemic and anti-platelet aggregation drugs

Also Published As

Publication number Publication date
EP1792616A1 (de) 2007-06-06
ES2336492T3 (es) 2010-04-13
BR9815548A (pt) 2000-11-07
JP4870869B2 (ja) 2012-02-08
IL134271A0 (en) 2001-04-30
AU752673B2 (en) 2002-09-26
JP2009235105A (ja) 2009-10-15
EP1017390B1 (de) 2007-04-18
WO1999006035A3 (en) 1999-04-22
US20090226518A1 (en) 2009-09-10
CY1107057T1 (el) 2012-10-24
DE69837610T2 (de) 2008-01-03
PT1017390E (pt) 2007-07-24
CA2298549A1 (en) 1999-02-11
JP2001511444A (ja) 2001-08-14
NZ520176A (en) 2005-02-25
ES2283067T3 (es) 2007-10-16
IL134271A (en) 2006-07-05
DK1017390T3 (da) 2007-06-11
ATE359785T1 (de) 2007-05-15
US20120164221A1 (en) 2012-06-28
WO1999006035A2 (en) 1999-02-11
DE69841395D1 (de) 2010-01-28
HK1106153A1 (en) 2008-03-07
CA2298549C (en) 2006-01-10
EP1792616B1 (de) 2009-12-16
AU8680198A (en) 1999-02-22
US20040053975A1 (en) 2004-03-18
EP1017390A2 (de) 2000-07-12
DE69837610D1 (de) 2007-05-31
NO20000439D0 (no) 2000-01-27
NO20000439L (no) 2000-03-22

Similar Documents

Publication Publication Date Title
ATE451926T1 (de) Zusammensetzung enthaltend einen hmg-coa- reduktasehemmer und eine nikotinsäureverbindung zur behandlung von hyperlipidämie
LU90230I2 (fr) Cerivastatine (INN) et ses sels et dérivés pharmaceutiquement acceptables (LIPOBAY )
IT8922768A0 (it) Composti attivi come inibitori dell'enzima hmg-coa reduttasi
EE200000659A (et) 4-(3,5-bis-trifluorometüülbensüülamino)-2-etüül-6-trifluorometüül-3,4-dihüdro-2H-kin oliin-1-karboksüülhappe etüülestrid või nende soolad ja valmistamise meetodid
EP0773022A3 (de) Pharmazeutische Zubereitung zur Behandlung akuter Rhinitiden, enthaltend Sympthomimeticum und Pantothenol und/oder Pantothensäure
DE69600001T2 (de) Kosmetische Zusammensetzung, die eine Silikonverbindung und einen Fettsäureester enthält
DE59401923D1 (de) Substituierte heterocyclische Carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
AU8995598A (en) Product and method for the treatment of hyperlipidemia
DE69523436T2 (de) Kosmetische Zusammensetzungen enthaltende Laktatedehydrogenase Hemstoffe
AU649699B2 (en) Substituted pyrroles
KR970706807A (ko) 메티오날 또는 말론디알데히드의 세포 내 비율에 영향을 미치는 성분을 함유하는 세포소멸(Capoptosis) 조절 조성물(APOPTOSIS-MODULATING COMPOSITION COMPRISING A FACTOR AFFECTING THE INTRACELLULAR RATE OF METHIONAL OR MALONDIALDEHYDE)
GB9718903D0 (en) Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents
BR0317520A (pt) Composições de inibidores de proteìna de transferência de ésteres de colesterilo e inibidores de hmg-coa redutase
DE69300062T2 (de) Verfahren zur Herstellung von N-Methoxyderivate von 4-Hydroxy-2,2,6,6-Tetramethylpiperidin und 2,2,6,6-Tetramethyl-4-Piperidon.
IT1237792B (it) Composti attivi come inibitori dell'enzima hmg-coa reduttasi
CA2385863A1 (en) New pyrimidine-2,4,6-trione derivatives, processes for their production and pharmaceutical agents containing these compounds
FR2687154B1 (fr) Nouveau derive de l'isoindolinone, sa preparation et les compositions pharmaceutiques qui le contiennent.
CO4940439A1 (es) COMPUESTOS 4-AMINO-6,7-DISUSTITUIDOS-PIRIDO-[2,3-d] PIRIMI- DINA
FI953957A (fi) 1,4-dihydropyridiini-3,5-dikarboksyylihappoestereiden käyttö lääkeaineena
CA2119777A1 (en) An Ameliorant for Blood Lipid Metabolism
AU3108393A (en) Specific 1,4-dihydropyridine-3,5-dicarboxylic acid ester, process for its preparation and its pharmaceutical use
NO960777D0 (no) Anvendelse av N-alkylerte 1,4-dihydropyridin dikarboksylsyreestere som medikamenter
WO2001091535A3 (en) A combination kit used in the treatment of malaria containing chloroquine and 3-(1-(((4-((6-methoxy-8-quinolinyl)amino)pentyl)amino)-ethylidene)-dihydro-2(3h)furanone enthält
DE59306506D1 (de) 4-Heterocyclyl substituierte Dihydropyridine
AU2806595A (en) Pyridonecarboxylic acid derivative, ester thereof, salt thereof, and intermediate for synthesis of these compounds

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties